Michael Makris/LinkedIn
Feb 28, 2026, 16:16
Michael Makris: Lower Doses of Hemlibra May Still Be Effective
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, shared on LinkedIn about his recent commentary, adding:
”The approved dose of Hemlibra (emicizumab) is generous, and smaller doses are likely to be effective.
You can read the arguments in my commentary published in the current issue of the Journal of Thrombosis and Haemostasis.”
Title: Is all the approved emicizumab dose essential?
Authors: Michael Makris
Read the Full Article on JTH
Stay updated on all scientific advances with Hemostasis Today.
-
Jun 19, 2026, 20:21Jonathan Penm: Julianne Chong Featured in Australian Pharmacist on Anticoagulation Stewardship
-
Jun 19, 2026, 20:18Yaariv Khaykin: Can Some Patients Safely Stop Blood Thinners After AF Ablation?
-
Jun 19, 2026, 20:18Ahmed Mohsen: How Should D-Dimer Be Interpreted in Pregnancy?
-
Jun 19, 2026, 20:17Konrad Zuzda: A Challenging Case of Heparin-Free VV-ECMO for High-Risk Airway Management
-
Jun 19, 2026, 19:52Andre W. Bourgoyne: Could Your Diet Help Prepare You for Surgery?
-
Jun 19, 2026, 18:00George Harston: How AI Is Supporting the Next Generation of Acute Stroke Care in AHA 2026 Guidelines
-
Jun 19, 2026, 17:49Jennifer Beauchamp: Exploring the New Era of Stroke Care at the 16th Annual Yatsu Day Symposium
-
Jun 19, 2026, 17:44Brian A Beh: How A Lacunar Stroke Changed Me
-
Jun 19, 2026, 17:40Cameron Bryer: Returning to Work After a Young Stroke Is Challenging but Possible